3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Glioblastoma
2
Brain Neoplasms
2
Adenocarcinoma of Lung
2
Urinary Bladder Neoplasms
1
Solid Tumor
1
Peripheral Nervous System Diseases
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
NSCLC
1
Myeloproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid
1
Leukemia
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Cytarabine
21
Imatinib Mesylate
20
venetoclax
16
Azacitidine
16
nilotinib
15
Cyclophosphamide
15
fludarabine
13
Dasatinib
12
blinatumomab
10
Rituximab
10
quizartinib
7
Gemtuzumab
7
Daunorubicin
7
ruxolitinib
6
Drug Therapy
6
Clofarabine
6
Bendamustine Hydrochloride
6
AP 1903 reagent
6
ponatinib
5
fludarabine phosphate
5
Whole-Body Irradiation
5
Vincristine
5
Mycophenolic Acid
5
Methotrexate
5
Granulocyte Colony-Stimulating Factor
5
Dexamethasone
5
vosaroxin
4
revumenib
4
rasburicase
4
forodesine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia
×
BID protein, human
×
Clear all
NCT02627677
2021-11-26
OPTIC-2L
Takeda
Phase 3
Terminated
44 enrolled
22 charts